Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer
30 Octubre 2023 - 6:00AM
Business Wire
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the
appointment of Jennifer Towne, Ph.D., as Executive Vice President
and Chief Scientific Officer, effective November 6, 2023. Dr. Towne
will be responsible for leading the Company’s research function
from basic research through scale-up manufacturing and the
introduction of drug candidates to clinical trials. She will report
to Vir’s Chief Executive Officer Marianne De Backer, M.Sc., Ph.D.,
MBA, and will join the Company’s Executive Management Team.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20231026830042/en/
Jennifer Towne, Ph.D., appointed as
Executive Vice President and Chief Scientific Officer at Vir
Biotechnology (Photo: Business Wire)
“Jennifer brings more than two decades of deep immunology
R&D experience that includes a proven track record of
successfully developing breakthrough medicines and bringing
multiple investigational new drug applications for innovative
therapeutics forward,” said Dr. De Backer. “Her scientific and
external innovation leadership experience combined with her
expertise in antibodies, biologics and leading-edge computational
tools will be critical to this role as we expand our aperture to
focus on viral-associated diseases and immune targeting as new
areas of growth, addressing patient need in infectious disease and
beyond.”
Dr. Towne joins Vir from The Janssen Pharmaceutical Companies of
Johnson & Johnson, where she spent nine years holding
immunology research leadership roles of increasing responsibility
within Research and Development. In her most recent role as Senior
Vice President, Immunology Discovery and External Innovation, she
was responsible for advancing disease understanding and development
of innovative therapeutics across autoimmune and inflammatory
diseases as well as for bringing the most promising early
innovation into Janssen to support the immunology portfolio. Prior
to Janssen, Dr. Towne held a variety of scientific roles during her
13 years at Amgen. During the course of her career, Dr. Towne led
the development of 16 drug candidates from preclinical research to
IND and clinical development.
“I’m honored to join Vir, a company with significant
accomplishments to-date, an exceptional research team and
world-class science,” said Dr. Towne. “I look forward to leading
the team and building upon the Company’s strong scientific
foundation to drive future growth opportunities and patient
impact.”
Dr. Towne earned her Ph.D. from the Department of Molecular
Genetics, Biochemistry, and Microbiology at the University of
Cincinnati College of Medicine in Cincinnati, Ohio. She also holds
a bachelor’s in biochemistry and a bachelor’s in biology from the
Department of Chemistry and Department of Biology at Whitworth
University in Spokane, WA.
About Vir Biotechnology
Vir Biotechnology, Inc. is an immunology company focused on
combining cutting-edge technologies to treat and prevent infectious
diseases and other serious conditions. Vir has assembled two
technology platforms that are designed to stimulate and enhance the
immune system by exploiting critical observations of natural immune
processes. Its current clinical development pipeline consists of
product candidates targeting hepatitis B and hepatitis delta
viruses and human immunodeficiency virus. Vir has several
preclinical candidates in its pipeline, including those targeting
influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts
information that may be important to investors on its website.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “plan,” “potential,” “aim,”
“expect,” “anticipate,” “promising” and similar expressions (as
well as other words or expressions referencing future events,
conditions or circumstances) are intended to identify
forward-looking statements. These forward-looking statements are
based on Vir’s expectations and assumptions as of the date of this
press release. Forward-looking statements contained in this press
release include, but are not limited to, statements regarding Vir’s
strategy and plans; Vir’s future financial and operating results
and its expectations related thereto; and potential of, and
expectations for, Vir’s pipeline. Many important factors may cause
differences between current expectations and actual results,
including unexpected safety or efficacy data or results observed
during clinical trials or in data readouts; the timing and outcome
of Vir’s planned interactions with regulatory authorities;
difficulties in obtaining regulatory approval; uncertainty as to
whether the anticipated benefits of Vir’s collaborations with other
companies can be achieved; difficulties in collaborating with other
companies; challenges in accessing manufacturing capacity; clinical
site activation rates or clinical trial enrollment rates that are
lower than expected; successful development and/or
commercialization of alternative product candidates by Vir’s
competitors; changes in expected or existing competition; delays in
or disruptions to Vir’s business or clinical trials due to the
COVID-19 pandemic, geopolitical changes or other external factors;
and unexpected litigation or other disputes. Drug development and
commercialization involve a high degree of risk, and only a small
number of research and development programs result in
commercialization of a product. Results in early-stage clinical
trials may not be indicative of full results or results from
later-stage or larger-scale clinical trials and do not ensure
regulatory approval. You should not place undue reliance on these
statements, or the scientific data presented. Other factors that
may cause actual results to differ from those expressed or implied
in the forward-looking statements in this press release are
discussed in Vir’s filings with the U.S. Securities and Exchange
Commission, including the section titled “Risk Factors” contained
therein. Except as required by law, Vir assumes no obligation to
update any forward-looking statements contained herein to reflect
any change in expectations, even as new information becomes
available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231026830042/en/
Media Carly Scaduto Senior Director, Media Relations
cscaduto@vir.bio +1-314-368-5189
Investors Sasha Damouni Ellis Executive Vice President,
Chief Corporate Affairs Officer sdamouni@vir.bio
Vir Biotechnology (NASDAQ:VIR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Vir Biotechnology (NASDAQ:VIR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024